TY  - JOUR
T1  - FDa expands age range for shingles vaccine
AU  - Voelker R
Y1  - 2011/04/20
N1  - 10.1001/jama.2011.495
JO  - JAMA
SP  - 1526
EP  - 1526
VL  - 305
IS  - 15
N2  - 
The agency based its approval on a multicenter study in the United States and 4 other countries of about 22 000 participants aged 50 to 59 years. Half received the vaccine and half received a placebo. After a year of follow-up, the vaccine reduced the risk of developing shingles by about 70% compared with placebo.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.495
UR  - http://dx.doi.org/10.1001/jama.2011.495
ER  -